Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression

Jonathan Kaufman, Efstathios Kastritis, Nisha Joseph et al. Nov 03, 2025 pp. 407-407 10.1182/blood-2025-407

Abstract INTRO In patients with newly diagnosed multiple myeloma (NDMM) four drug induction therapy is associated with improved outcomes with...

When supportive care backfires: G-CSF induced aortitis unmasked during routine adjuvant chemotherapy

Sushmithaa Ramesh, Venumadhavi Gogineni, Adam Forman Nov 03, 2025 pp. 6566-6566 10.1182/blood-2025-6566

Abstract Case Summary: In today's fast-paced oncology world, where patient volume is only increasing, the ability to recognize rare but seri...

Prognostic impact of transplant conditioning intensity (TCI) score and minimal identifiable disease (MID) in MDS: A multicenter trophy group study

Ruoxuan Zhang, Yang Cao, Hua Jin et al. Nov 03, 2025 pp. 4205-4205 10.1182/blood-2025-4205

Abstract Background: Due to the heterogeneity of myelodysplastic syndromes (MDS) and variations in patient characteristics, the optimal cond...

Outcomes for Medicaid recipients with multiple myeloma: A national retrospective trend analysis from 2015 to 2022

Tony Elias, Danielle Thor, Vineet Polineni et al. Nov 03, 2025 pp. 8117-8117 10.1182/blood-2025-8117

Abstract Introduction: Despite global decreases in overall cancer incidence, the incidence of multiple myeloma (MM) continues to increase at...

The ratio of post-infusion circulating PD-1+ CAR-T subsets to product PD-1+ CAR-T cells serves as a predictive biomarker for long-term disease control in CAR T-cell therapy for R/R B-cell lymphoma

Fan Yang, Rui Liu, Zhonghua Fu et al. Nov 03, 2025 pp. 2377-2377 10.1182/blood-2025-2377

Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy has proven to be a standard of care (SOC) for patients with relapsed/ref...

Preclinical evaluation of macrophage reprogramming in treatment of CTCL

Madeline Williams, PyungHun Park, Carla Portocarrero et al. Nov 03, 2025 pp. 5347-5347 10.1182/blood-2025-5347

Abstract Introduction: Reprogramming tumor-supportive macrophages may have therapeutic utility in cutaneous T-cell lymphoma (CTCL) (Wu et al...

Predicting survival outcomes in CAR-t treated B-cell lymphoma by combining PET/CT imagingand clinical features

Blanca Ferrer Lores, Laura Ventura-López, Alejandra Estepa-Fernández et al. Nov 03, 2025 pp. 5487-5487 10.1182/blood-2025-5487

Abstract Background Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative option for relapsed/refractory (R/R) B-...

Allogeneic hematopoietic cell transplantation for infantile osteopetrosis: High rates of sinusoidal obstruction syndrome/veno-occlusive disease and transplant-related morbidity

Marketa Dimitrov, Alex Hoover, Ryan Shanley et al. Nov 03, 2025 pp. 7730-7730 10.1182/blood-2025-7730

Abstract Introduction Osteopetrosis is a group of heterogeneous inherited disorders characterized by osteoclast dysfunction-driven dysregula...

Nemtabrutinib in participants with relapsed or refractory follicular lymphoma: Updated efficacy and safety from cohort g of the phase 2 bellwave-003 study

Wojciech Jurczak, Ana Basquiera, Isabelle Fleury et al. Nov 03, 2025 pp. 3570-3570 10.1182/blood-2025-3570

Abstract Introduction: Covalent Bruton tyrosine kinase inhibitors (BTKis) have shown clinical activity as monotherapy in relapsed or refracto...

CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study

Andre Schuh, Pau Montesinos, Christian Récher et al. Nov 03, 2025 pp. 3440-3440 10.1182/blood-2025-3440

Abstract Introduction Ivosidenib (IVO) is an oral, targeted, small-molecule inhibitor of mIDH1 approved for the treatment of pts with mIDH1 A...

Socioeconomic inequalities and health-related quality of life profile of patients with Myelodysplastic Syndromes (MDS): Analysis of 504 patients with higher-risk MDS

Francesco Sparano, Giovanni Caocci, Pasquale Niscola et al. Nov 03, 2025 pp. 6389-6389 10.1182/blood-2025-6389

Abstract Background Socioeconomic status (SES) is a known factor frequently associated with health-related quality of life (HRQoL) in oncolo...

Early vs late plasmapheresis in TTP: A u.s. national study on in-hospital mortality

Barath Sivasubramanian, Gagan Kumar, Achuta Kumar Guddati Nov 03, 2025 pp. 3104-3104 10.1182/blood-2025-3104

Abstract Introduction Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy that re...

An evaluation of the relationship between abnormal myocardial perfusion and diastolic dysfunction in sickle cell disease using PET rest-stress myocardial perfusion imaging: Mypers

Parul Rai, R Morrison, Kendria Barnes et al. Nov 03, 2025 pp. 1199-1199 10.1182/blood-2025-1199

Abstract Background: The morbidity and mortality burden of cardiac complications, including diastolic dysfunction (DD), is significant in si...

N-glycosylation of monoclonal immunoglobulins across plasma cell dyscrasias in routine care: A cohort study using EXENT® mass spectrometry

Lauren Campbell, Oluremi Carty, Jessie Kaur et al. Nov 03, 2025 pp. 7562-7562 10.1182/blood-2025-7562

Abstract Background: N-glycosylation of monoclonal immunoglobulin light chains is increasingly recognised as a potential...

Survival outcomes for newly diagnosed non-germinal center large B cell lymphoma patients treated with R-CHOP based on double expressor status and genomic features

Alyssa Klein, Sunita Dwivedy Nasta, Stefan Barta et al. Nov 03, 2025 pp. 1891-1891 10.1182/blood-2025-1891

Abstract Background Previous work has linked the inferior prognosis of patients with newly diagnosed large B cell lymphoma (LBCL) of activat...

Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project

Simone Ragaini, Katja Gutmair, Riccardo Moia et al. Nov 03, 2025 pp. 5299-5299 10.1182/blood-2025-5299

Abstract Introduction The TRIANGLE trial (Dreyling et al, Lancet 2024) compared three treatment arms in untreated, younger patients with man...

Real world experience with brecadd protocol as frontline therapy for patients with advanced stage classical Hodgkin lymphoma: A multicenter retrospective study

Tzvika Porges, Tsofia Levi, Eldad Dann et al. Nov 03, 2025 pp. 3618-3618 10.1182/blood-2025-3618

Abstract Introduction: Traditionally, the management of patients with advanced-stage classical Hodgkin lymphoma (cHL) re...

Utilization and outcomes of erythropoietin stimulating agents in sickle cell disease patient: A real world data analysis

Devashish Desai, Deevyashali Parekh, Prashanth Ashok Kumar Nov 03, 2025 pp. 1197-1197 10.1182/blood-2025-1197

Abstract Background: Sickle cell disease (SCD) is hereditary blood disorder leading to anemia, vaco-occlusive crises, organ damage. Its trea...

Cytotoxic CD8⁺ T cells are required for CD20xCD3 bispecific antibody-mediated tumor control in B-cell non-Hodgkin lymphomas

Philipp Berning, Kazuya Fukasawa, Jahan Rahman et al. Nov 03, 2025 pp. 556-556 10.1182/blood-2025-556

Abstract Background: CD20xCD3 bispecific antibodies (BsAb) are a transformative therapy for B-cell non-Hodgkin lymphomas (B-NHL), effective...

Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy

Fan Yang, Rui Liu, Yuelu Guo et al. Nov 03, 2025 pp. 5484-5484 10.1182/blood-2025-5484

Abstract Background: The prognosis for patients with refractory/relapsed aggressive B-cell lymphoma (R/R B-NHL) who have failed CD19 CAR-T c...

Diffuse large B cell lymphoma: A study of second primary malignancies among adults in the United States

Oboseh Ogedegbe, Olanipekun Lanny Ntukidem, Manas Pustake et al. Nov 03, 2025 pp. 3680-3680 10.1182/blood-2025-3680

Abstract Background: Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-hodgkin lymphoma (NHL), accounting for up to 30...

TP53 aberrant Mantle Cell Lymphoma treated with first-line systemic therapy: A real-world analysis of outcomes in 120 patients treated in the United Kingdom

Rory McCulloch, Sunil Iyengar, Jessica Okosun et al. Nov 03, 2025 pp. 1827-1827 10.1182/blood-2025-1827

Abstract Background: Alterations to the tumor suppressorTP53 in mantle cell lymphoma (MCL) are one of the strongest predictors of poor respo...

Dose dense rituximab for high-risk children and adolescents with newly diagnosed acute immune thrombocytopenic purpura (ITP) (NCT04323748)

Edo Schaefer, Ashley Pinchinat, Dana Chersi et al. Nov 03, 2025 pp. 3042-3042 10.1182/blood-2025-3042

Abstract Background: Immune thrombocytopenic purpura (ITP) is an immune-mediated bleeding disorder, occurring mainly in young children, with...

Predicting donor engraftment success in adults post haploidentical bone marrow transplant for sickle cell disease: BMT CTN 1507

Joshree Shrestha, Cecilia Motta, Michael Keller et al. Nov 03, 2025 pp. 2472-2472 10.1182/blood-2025-2472

Abstract Introduction: Hematopoietic Cell Transplant (HCT) using a HLA-haploidentical donor greatly expands access to cu...

Beyond the trial: Real-world CRS, icans, and healthcare burden of CAR T-cell therapy across US oncology practices

Taiga Nishihori, Li Chen, Benjamin Wagner et al. Nov 03, 2025 pp. 6263-6263 10.1182/blood-2025-6263

Abstract Background:Chimeric antigen receptor T-cell therapy (CAR T) has improved outcomes in relapsed/refractory diffuse large B-cell lymph...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page